|
|
|
|
|
|
|
The latest developments in clinical care, research and cost during COVID through the lens of health plans, academic cancer centers, health systems, pharma, government and providers / oncology groups; what has happened over the last 12 months, anda look into the post-COVID future.
The future of cancer diagnosis and treatment post-COVID.
New hybrid partnerships being formed to facilitate innovation during the pandemic.
The relationship between cancer immunotherapy and COVID vaccines.
The realities and challenges of innovative new cancer modalities.
The use of large data analytics to improve outcomes, clinical research and cost.
|
|
|
|
|
|
|
|
|
New innovations and technology that encourage people to seek care, and improve diagnosis, patient-centered and integrated care, survivorship programs, and palliative care.
The acceleration of virtual/telemedicine diagnostics and treatment modalities.
How genomics, precision medicine, immunotherapeutic and biosimiliar therapies will change the future of cancer care.
How to plan for the future in response to the challenges and opportunities of the new normal: post-COVID innovative new cancer treatments.
The impact of COVID on cancer patients and families, and how it is being addressed with respect to the social determinants of health.
What's getting in our way of moving forward in these areas.
|
|
|
|
|
|
|
|
|
|